Certara, Inc. (NASDAQ:CERT) Given Average Rating of “Hold” by Analysts

Certara, Inc. (NASDAQ:CERT) has been given an average rating of “Hold” by the thirteen analysts that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $8.95.

Several brokerages have recently commented on CERT. Craig Hallum lowered their price objective on Certara from $10.00 to $8.00 and set a “hold” rating for the company in a research note on Tuesday, May 12th. KeyCorp lowered their target price on shares of Certara from $10.00 to $8.00 and set an “overweight” rating on the stock in a report on Monday, April 13th. Barclays upped their price target on shares of Certara from $6.50 to $7.50 and gave the stock an “equal weight” rating in a report on Wednesday. Robert W. Baird cut their target price on shares of Certara from $7.00 to $6.00 and set a “neutral” rating for the company in a research report on Tuesday, May 12th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Certara in a report on Friday, May 29th.

Certara Stock Up 2.7%

Shares of NASDAQ CERT opened at $8.01 on Thursday. The stock has a 50-day moving average price of $6.47 and a two-hundred day moving average price of $6.55. Certara has a 12 month low of $4.45 and a 12 month high of $13.88. The company has a current ratio of 2.55, a quick ratio of 1.88 and a debt-to-equity ratio of 0.30. The company has a market cap of $1.25 billion, a price-to-earnings ratio of -17.80 and a beta of 1.44.

Certara (NASDAQ:CERT) last posted its earnings results on Tuesday, August 4th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). Certara had a positive return on equity of 3.86% and a negative net margin of 16.75%.The business had revenue of $93.27 million for the quarter, compared to the consensus estimate of $98.09 million. During the same period in the previous year, the firm earned $0.07 earnings per share. The company’s revenue was down 10.8% compared to the same quarter last year. As a group, analysts forecast that Certara will post 0.24 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. AQR Capital Management LLC purchased a new position in Certara during the 1st quarter valued at about $259,000. Goldman Sachs Group Inc. grew its stake in shares of Certara by 65.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 228,996 shares of the company’s stock worth $2,267,000 after buying an additional 90,724 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Certara by 13.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 299,528 shares of the company’s stock valued at $2,965,000 after buying an additional 35,954 shares in the last quarter. Jane Street Group LLC boosted its holdings in Certara by 17.1% in the first quarter. Jane Street Group LLC now owns 277,054 shares of the company’s stock worth $2,743,000 after acquiring an additional 40,463 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its stake in shares of Certara by 29.3% in the second quarter. JPMorgan Chase & Co. now owns 93,057 shares of the company’s stock worth $1,089,000 after acquiring an additional 21,099 shares during the last quarter. Hedge funds and other institutional investors own 73.96% of the company’s stock.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.